230 related articles for article (PubMed ID: 9758315)
1. Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature.
Johnson MD; Drew RH; Perfect JR
Pharmacotherapy; 1998; 18(5):1053-61. PubMed ID: 9758315
[TBL] [Abstract][Full Text] [Related]
2. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
3. Liposomal amphotericin B in neonates with invasive candidiasis.
Al Arishi H; Frayha HH; Kalloghlian A; Al Alaiyan S
Am J Perinatol; 1998; 15(11):643-8. PubMed ID: 10064206
[TBL] [Abstract][Full Text] [Related]
4. Liposomal amphotericin B: clinical experience and perspectives.
Gibbs WJ; Drew RH; Perfect JR
Expert Rev Anti Infect Ther; 2005 Apr; 3(2):167-81. PubMed ID: 15918775
[TBL] [Abstract][Full Text] [Related]
5. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
6. [Neonatal candidiasis and liposomal amphotericin B treatment: our experience].
Carrasco Sánchez P; Castillo Montero ML; Bejarano Palma A; López Sanz A; Santano Gallinato M; Sáenz Reguera C; Durán de Vargas L; González-Meneses A
An Esp Pediatr; 1999 Sep; 51(3):273-80. PubMed ID: 10575751
[TBL] [Abstract][Full Text] [Related]
7. Nephrogenic diabetes insipidus induced by two amphotericin B liposomal formulations.
Metzger NL; Varney Gill KL
Pharmacotherapy; 2009 May; 29(5):613-20. PubMed ID: 19397468
[TBL] [Abstract][Full Text] [Related]
8. Case-control study of amphotericin B in a triglyceride fat emulsion versus conventional amphotericin B in patients with AIDS.
Manfredi R; Chiodo F
Pharmacotherapy; 1998; 18(5):1087-92. PubMed ID: 9758320
[TBL] [Abstract][Full Text] [Related]
9. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
[TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B for the treatment of severe fungal infection.
Michaud D
Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
[TBL] [Abstract][Full Text] [Related]
11. Amphotericin B--not so terrible.
Bishara J; Weinberger M; Lin AY; Pitlik S
Ann Pharmacother; 2001 Mar; 35(3):308-10. PubMed ID: 11261528
[TBL] [Abstract][Full Text] [Related]
12. Liposomal amphotericin B in neonates with invasive candidiasis.
al Arishi H; Frayha HH; Kalloghlian A; al Alaiyan S
Am J Perinatol; 1997 Oct; 14(9):573-6. PubMed ID: 9394170
[TBL] [Abstract][Full Text] [Related]
13. Use of liposomal amphotericin B in bone marrow transplant.
Sastry PS; Parikh PM; Kulkarni PS; Bhagwat R; Gadade H
J Postgrad Med; 2005; 51 Suppl 1():S49-52. PubMed ID: 16519256
[TBL] [Abstract][Full Text] [Related]
14. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.
Cordonnier C; Mohty M; Faucher C; Pautas C; Robin M; Vey N; Monchecourt F; Mahi L; Ribaud P
Int J Antimicrob Agents; 2008 Feb; 31(2):135-41. PubMed ID: 18162375
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.
Walsh TJ; Goodman JL; Pappas P; Bekersky I; Buell DN; Roden M; Barrett J; Anaissie EJ
Antimicrob Agents Chemother; 2001 Dec; 45(12):3487-96. PubMed ID: 11709329
[TBL] [Abstract][Full Text] [Related]
16. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Ullmann AJ; Bouza E; Heussel CP; Lortholary O; Rieger C; Boehme A; Aoun M; Horst HA; Thiebaut A; Ruhnke M; Reichert D; Vianelli N; Krause SW; Olavarria E; Herbrecht R;
Clin Infect Dis; 2007 May; 44(10):1289-97. PubMed ID: 17443465
[TBL] [Abstract][Full Text] [Related]
17. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of pulmonary blastomycosis with continuously infused amphotericin B deoxycholate after failure with liposomal amphotericin B.
Ariano RE; Mitchelmore BR; Lagacé-Wiens PR; Zelenitsky SA
Ann Pharmacother; 2013 Jun; 47(6):e26. PubMed ID: 23673538
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group.
Wingard JR; White MH; Anaissie E; Raffalli J; Goodman J; Arrieta A;
Clin Infect Dis; 2000 Nov; 31(5):1155-63. PubMed ID: 11073745
[TBL] [Abstract][Full Text] [Related]
20. Treatment of neonatal candidiasis with liposomal amphotericin B(L-AMP-LRC-1): phase II study.
Kotwani RN; Bodhe PV; Kirodian BG; Mehta KP; Ali US; Kshirsagar NA
Indian Pediatr; 2003 Jun; 40(6):545-50. PubMed ID: 12824664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
